枸杞多糖对甲型H1N1流感裂解疫苗黏膜接种的免疫增强作用

探讨枸杞多糖(Lycium barbarum polysaccharide,LBP)对不同剂量甲型H1N1流感裂解疫苗黏膜免疫的佐剂效力。设单独免疫LBP组和不免疫组作为对照,BALB/c小鼠以滴鼻方式免疫两次,间隔三周,二次免疫后两周收集小鼠血清、鼻洗液和脾脏淋巴细胞。结果显示血清中甲流特异性IgG和HI抗体滴度与接种疫苗剂量呈正相关,LBP的添加可提高体内抗体水平。高剂量组小鼠鼻洗液中也检测到特殊异性sIgA。单独疫苗组和添加佐剂组均能在体内诱导产生IgG1和IgG2a,所有组别IgG1抗体水平均略高于IgG2a,表明滴鼻接种裂解疫苗诱导Th1/Th2混合型免疫,LBP对Th1和Th2型免疫反应均有增强作用。高剂量疫苗添加LBP佐剂组小鼠脾脏细胞分泌IFN-γ水平显著高于其他组别,表明其在小鼠体内诱导了较强烈的细胞免疫反应。以上实验结果均证实LBP可以作为佐剂增强甲流裂解疫苗经黏膜途径免疫时的免疫效力。     

流感新型黏膜疫苗的研究

目的评价PorA、PorB和Class4对流感裂解疫苗的免疫增强作用,从中挑选出最有效的流感黏膜佐剂,为发展流感黏膜疫苗提供理论基础。方法流感三价裂解抗原按比例与PorA、PorB和Class4非共价结合,滴鼻免疫Balb／c小鼠3次,采取间接ELISA检测血清特异性IgG抗体及抗体亚型,检测鼻咽、肺、小肠和阴道冲洗液中IgA效价,采用血凝抑制试验检测血清中HAI效价。结果PorB重组蛋白佐剂组较无佐剂的流感裂解抗原组在提高小鼠早期免疫应答的同时诱导较强的系统免疫应答和黏膜免疫应答;PorA组也有黏膜佐剂的功能,但和无佐剂的流感裂解抗原组相比,差异无统计学意义。结论在蛋白体的三分子中,以PorB为佐剂的流感黏膜疫苗不仅提高了抗原的系统免疫应答,而且诱导了较强的小鼠呼吸道、生殖道的局部黏膜免疫应答,为流感黏膜疫苗的研制奠定了理论基础。     

SARS-CoV-2 Beta变异株和甲型流感病毒H3N2双价重组腺病毒载体疫苗可在小鼠诱导免疫保护

评价一种SARS-CoV-2 Beta变异株和甲型流感病毒H3N2新型重组双价疫苗在小鼠模型中的免疫保护效果。本研究构建了表达SARS-CoV-2南非变异株(B.1.351)棘突蛋白1(S1)和H3N2柬埔寨分离株(A/Cambodia/e0826360/2020)血凝素(HA)的重组双价非复制Ad5载体疫苗,命名为HAdV5-S1-2A-HA,经单针肌肉注射免疫BALB/c雌鼠后,采用ELISA、血凝抑制实验、假病毒中和实验与Elispot实验进行体液与细胞免疫学检测,免后3～6周采用H3N2-X31病毒、H1N1-PR8与SARS-CoV-2(B.1.351)进行攻毒保护实验。HAdV5-S1-2A-HA免疫两周后,低剂量组(1×10⁸vp/只)免疫小鼠后可检出HA特异体液免疫与S1特异的细胞免疫应答;而高剂量组(5×10⁹vp/只)诱导小鼠产生了较强的双抗原(S1,HA)特异的体液和细胞免疫应答,并能完全保护小鼠对H3N2-X31攻击,降低SARS-CoV-2(B.1.351)感染后小鼠肺部病毒载量,延迟H1N1-PR8病毒感染后小鼠死...     

不同黏膜佐剂对猪丁型冠状病毒诱导小鼠免疫应答的影响

【目的】旨在为猪丁型冠状病毒(porcine deltacoronavirus,PDCoV)灭活疫苗黏膜免疫筛选理想佐剂,降低疫苗副作用。利用小鼠模型评价不同佐剂制备的PDCoV灭活疫苗对体液免疫、细胞免疫和黏膜免疫应答的影响。【方法】将甘露聚糖肽(PA)、CpGODN2395、单磷酰脂质A(MPLA)佐剂分别与IMS 1313、GEL02佐剂联合制备PDCoV灭活疫苗,经鼻腔免疫BALB/c小鼠;将ISA201佐剂制备的PDCoV灭活疫苗经皮下免疫BALB/c小鼠,将PDCoV灭活抗原经鼻腔免疫BALB/c小鼠作为对照,间隔14 d加强免疫一次。用ELISA方法检测小鼠血清、支气管肺泡灌洗液(BALF)中的IgG、IgG1、IgG2a、IL-4、IFN-γ及粪便和BALF中sIgA表达水平;用MTT方法检测疫苗免疫后对小鼠脾淋巴细胞增殖的影响;观察并记录小鼠免疫后的临床表现,HE染色方法观察免疫小鼠主要器官组织的病理学变化,评价疫苗的安全性。【结果】ISA201组小鼠BALF和血清中的抗体(IgG、IgG1)及IL-4表达水平相对较高,但IgG2a、IFN-γ和粪便中sIgA表达水平...     

抗EHFV的独特型抗体在小鼠体内诱导免疫应答的研究

本文介绍用流行性出血热（EHF）病毒J10株制备单克隆抗体（McAb）,以及用7个McAb免疫家兔,使其产生抗EHF病毒McAb的抗体即抗独特型 抗体（Ab2).Ab2能在体外同出血热病人恢复期血清和EHF病毒免疫的兔血清发生特异性结合。再经EHF－McAb亲和层析法分离提纯Ab2,免疫BALb/c小鼠,将所获得的免疫血清（Ab3）用荧光和ELISA分别加以测定。结果表明,抗－抗独特型抗体可在体外识别EHF病毒,而不能同病病人恢复期血清发生结合,从而支持免疫网络学说,可能为我们提供一种新型的抗原来源途径。     

乙肝患者抗HBs独特型抗体特异性免疫复合物的检测与意义

根据用终浓度分别为35.0g/L和17.5g/L聚乙二醇沉淀循环免疫复合物,去除游离抗HBs-Ab_2,再以胰蛋白酶解离复合物的原理,建立了检测抗HBs-Ab_2-ICs的ELISA法。结果表明,38例急性乙型肝类和83例慢性活动性乙肝患者的IgG、IgM类抗HBs-Ab_2-ICs总阳性率分别为13.2％(5/38)和18.1％(15/83)。IgG、IgM类抗HBs-Ab_2-ICs检出率无显著差异(P>0.05)。实验证实乙肝患者体内存在含抗HBs-Ab_2-ICs。提示抗HBs-Ab_2尚可与抗HBs结合,抑制其中和HBV的作用而利于HBV复制。     

滴鼻免疫有效的诱导粘膜及系统免疫反应

为了探讨粘膜疫苗滴鼻免疫对小鼠不同粘膜部位和系统免疫部位的影响,将BALB/c小鼠随机分为三组,每组15只,FSM-2117或FS-5416 4×107cfu/只经滴鼻途径免疫小鼠,间隔两周,4次免后7天活杀,收集鼻咽、肺、肠、生殖道冲洗液和血清,ELISA法检测其中特异性抗福氏、宋内氏LPSIg和AIgG;分离NALT、鼻通道、脾、小肠PP淋巴细胞,细胞中加入全菌破碎抗原共培养,于不同时间取出细胞,提取RNA做RT-PCR.两株菌苗经鼻内免疫均诱发了鼻咽、肺、胃肠道和生殖道等不同粘膜部位及血清中特异性抗福氏、宋内氏LPSIgA、IgG的显著增加(P＜0.01);免疫动物的NALT、NP、PP结淋巴细胞在体外经抗原刺激后均在不同时间出现IFN-γ和IL-4mRNA的表达,而TGF-β mRNA的表达在免疫前后无明显变化.疫苗经鼻粘膜免疫可诱导不同粘膜部位及系统免疫反应的发生,鼻粘膜是一个安全有效的免疫途径.     

黏膜抗体在疫苗免疫效力评价中的前景

简单介绍目前疫苗效力检验的方法、黏膜抗体的功能及其在实验室疫苗效果效力评价中的应用,提出了黏膜抗体作为疫苗免疫效力试验的替代指标或免疫监测的主要抗体的建议。     

H1N1裂解疫苗辅以C48/80佐剂滴鼻免疫小鼠能够提供抗甲流的保护作用

2009年"甲型H1N1流感"全球流行导致了数以万计人的死亡。疫苗的及时研制为预防、控制甲流的传播,减少发病率和死亡率做出了重大贡献。甲流疫苗辅以佐剂滴鼻免疫能更好地抵御甲流攻击。将A/California/7/2009(H1N1)裂解疫苗辅以化合物48/80(C48/80)佐剂滴鼻免疫雌性BALB/c小鼠,免疫一次,免疫后28 d,小鼠用致死剂量的同源病毒进行攻击。结果发现,滴鼻免疫组的抗体滴度均达到很高的水平,而且随着H1N1裂解疫苗剂量的增加,其对小鼠的保护作用越强,同时添加佐剂可以更有效提高H1N1裂解疫苗的保护效果。实验结果说明H1N1裂解疫苗辅以C48/80佐剂滴鼻免疫能够保护小鼠免受流感病毒的感染。     

Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice

Influenza virus infection frequently causes complications and some excess mortality in the patients with diabetes. Vaccination is an effective measure to prevent influenza virus infection. In this paper, antibody response and protection against influenza virus infection induced by vaccination were studied in mouse model of diabetes. Healthy and diabetic BALB/c mice were immunized once or twice with inactivated influenza virus vaccine at various dosages. Four weeks after the first immunization or 1 week after the second immunization, the mice were challenged with influenza virus at a lethal dose. The result showed that the antibody responses in diabetic mice were inhibited. Immunization once with high dose or twice with low dose of vaccine provided full protection against lethal influenza virus challenge in diabetic mice, however, in healthy mice, immunization only once with low dose provided a full protection.     

Protection of mice from rabies by intranasal immunization with inactivated rabies virus.

The mucosal immunization method is a needle-free alternative way of vaccination. This study evaluated the efficacy of mucosal immunization for rabies. Mice were intranasally administered five times with inactivated and concentrated rabies virus antigen (CRV) supplemented with or without cholera toxin (CT). The anti-rabies virus antibody titer of mice intranasally immunized with CRV plus CT (CRV/CT) was comparable to that of mice intraperitoneally immunized twice with the same amount of CRV. Virus neutralizing (VNA) titers of mice immunized intranasally with CRV/CT were slightly lower than those of intraperitoneally immunized mice. Both anti-rabies virus ELISA antibody and VNA titers of mice immunized with CRV without CT were significantly lower than those of mice immunized with CRV/CT. In mice intranasally immunized with CRV/CT, and intraperitoneally immunized mice, high levels of IgG(2a) antibody were detected, suggesting the activation of Th1-driven cellular immunity by the two ways of immunization. All immunized mice were challenged intracerebrally with a lethal dose of virulent rabies virus CVS strain. The survival rates of mice immunized with CRV/CT and CRV without CT were 67% and 17%, respectively, while the rate of intraperitoneally immunized mice was 100%. Antigen-specific whole IgG and IgG(2a), and VNA titers of survived mice were significantly higher than those of dead mice at the challenge day. These data suggest the possibility of intranasal immunization with inactivated antigen as a rabies vaccination strategy and the importance of a mucosal adjuvant such as CT.     

Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization

Both circulating and mucosal antibodies are considered important for protection against infection by influenza virus in humans and animals. However, current inactivated vaccines administered by intramuscular injection using a syringe and needle elicit primarily circulating antibodies. In this study, we report that epidermal powder immunization (EPI) via a unique powder delivery system elicits both serum and mucosal antibodies to an inactivated influenza virus vaccine. Serum antibody responses to influenza vaccine following EPI were enhanced by codelivery of cholera toxin (CT), a synthetic oligodeoxynucleotide containing immunostimulatory CpG motifs (CpG DNA), or the combination of these two adjuvants. In addition, secretory immunoglobulin A (sIgA) antibodies were detected in the saliva and mucosal lavages of the small intestine, trachea, and vaginal tract, although the titers were much lower than the IgG titers. The local origin of the sIgA antibodies was further shown by measuring antibodies released from cultured tracheal and small intestinal fragments and by detecting antigen-specific IgA-secreting cells in the lamina propria using ELISPOT assays. EPI with a single dose of influenza vaccine containing CT or CT and CpG DNA conferred complete protection against lethal challenges with an influenza virus isolated 30 years ago, whereas a prime and boost immunizations were required for protection in the absence of an adjuvant. The ability to elicit augmented circulating antibody and mucosal antibody responses makes EPI a promising alternative to needle injection for administering vaccines against influenza and other diseases.     

IFIT家族基因抑制A型流感病毒WSN毒株的复制和转录

IFIT(Interferon induced proteins with tetratricopeptide repeats)家族基因是一组较早发现的干扰素刺激基因,它在抗病毒和免疫调节中发挥了重要作用。为研究IFIT家族基因抑制A型流感病毒复制的机理,利用高通量RNA深度测序(RNA-Seq)技术发现A型流感病毒A/WSN/33(WSN)毒株感染293T细胞后,IFIT家族基因均出现明显上调。同时发现在IFIT2、IFIT3过表达后,流感病毒的复制和转录均有明显下调,并对v RNP聚合酶活性具有剂量依赖型的抑制作用。进一步研究证明在感染IFIT2、IFIT3编码蛋白与流感病毒非结构蛋白(NS1)存在细胞内共定位,证明二者存在相互作用的可能。综上所述,IFIT家族基因可以抑制A型流感病毒的复制和转录,有助于进一步阐明宿主因子对流感病毒感染的调节机制。     

Human immune responses elicited by an intranasal inactivated H5 influenza vaccine

Intranasally administered influenza vaccines could be more effective than injected vaccines, because intranasal vaccination can induce virus-specific immunoglobulin A (IgA) antibodies in the upper respiratory tract, which is the initial site of infection. In this study, immune responses elicited by an intranasal inactivated vaccine of influenza A(H5N1) virus were evaluated in healthy individuals naive for influenza A(H5N1) virus. Three doses of intranasal inactivated whole-virion H5 influenza vaccine induced strong neutralizing nasal IgA and serum IgG antibodies. In addition, a mucoadhesive excipient, carboxy vinyl polymer, had a notable impact on the induction of nasal IgA antibody responses but not on serum IgG antibody responses. The nasal hemagglutinin (HA)-specific IgA antibody responses clearly correlated with mucosal neutralizing antibody responses, indicating that measurement of nasal HA-specific IgA titers could be used as a surrogate for the mucosal antibody response. Furthermore, increased numbers of plasma cells and vaccine antigen-specific Th cells in the peripheral blood were observed after vaccination, suggesting that peripheral blood biomarkers may also be used to evaluate the intranasal vaccine-induced immune response. However, peripheral blood immune cell responses correlated with neutralizing antibody titers in serum samples but not in nasal wash samples. Thus, analysis of the peripheral blood immune response could be a surrogate for the systemic immune response to intranasal vaccination but not for the mucosal immune response. The current study suggests the clinical potential of intranasal inactivated vaccines against influenza A(H5N1) viruses and highlights the need to develop novel means to evaluate intranasal vaccine-induced mucosal immune responses.     

Adjuvant effect ofBacillus firmus in intranasal immunization of guinea pigs with inactivated type B influenza virus

Intranasal immunization of guinea pigs with inactivated type B influenza virus plus inactivated Bacillus firmus as an adjuvant compared to the virus alone yields higher titers of serum hemagglutination-inhibiting antibodies and virus-neutralizing antibodies. This phenomenon could be useful in standard serology, especially in the preparation of immune sera against highly pathogenic strains for in vitro diagnosis.     

Interaction between granulocytes and antibodies in the enhancement of lung defenses against Staphylococcus aureus after intranasal immunization of mice with live-attenuated bacteria

Abstract Immunization with live-attenuated Staphylococcus aureus induced measurable levels of specific IgG and IgA in the lungs, but the pulmonary clearance of S. aureus in immunized mice did not differ from that of control mice. Aerosol exposure of mice to Pseudomonas aeruginosa induced a significant recruitment of polymorphonuclear leukocytes (PMNL) to the lungs in both immunized and control mice, whereas S. aureus challenge did not. However, challenge with a mixture of P. aeruginosa-S. aureus or exposure to an aerosol of Escherichia coli lipopolysaccharide (LPS) before S. aureus challenge induced PMNL migration and a significant enhancement of pulmonary clearance of S. aureus in immunized mice. The presence of both antibodies and PMNL was required for enhancement of S. aureus pulmonary clearance.     

The role of oxidative stress in influenza virus infection

Virus-induced oxidative stress plays an important role in the regulation of the host immune system. In this review, we provide backgrounds of the pathogenic mechanism of oxidative stress induced by influenza virus and the specific oxidant-sensitive pathways, and highlight that antioxidant is one of the effective strategies against influenza virus infection.     

灭活贝氏柯克斯体免疫小鼠抗登革病毒感染的实验研究

目的 研究灭活贝氏柯克斯体增强小鼠非特异性抗登革病毒感染的免疫效能。方法 用灭活贝氏柯克斯体全细胞疫苗(WCV)免疫BALB/c小鼠,每只小鼠皮下注射50μg WCV,初次免疫后第5周及第7周分别腹腔注射20μg WCV加强免疫。1周后,用10~5 TCID_(50)剂量的登革病毒2型经尾静脉注入感染小鼠,于感染后48、72h分别解剖小鼠.自血和脑组织提取RNA样本,用实时荧光定量聚合酶链反应(PCR)检测样本。结果 用登革病毒特异的定量PCR检测感染小鼠血RNA样本,结果显示感染72h血样本中病毒含量显著低于48h样本,但免疫小鼠与未免疫小鼠之间无显著差异。检测脑组织RNA样本,未免疫小鼠和免疫小鼠的感染48h样本检出病毒均为少量;但未免疫小鼠感染96h样本检出病毒量明显增加,显著高于免疫小鼠。结论 灭活贝氏柯克斯体可诱导机体产生非特异的免疫应答,具有一定增强小鼠抗登革病毒感染的能力,但具体机制有待进一步研究。     

Nucleoprotein of influenza B virus binds to its type A counterpart and disrupts influenza A viral polymerase complex formation

Upon co-infection with influenza B virus (FluB), influenza A virus (FluA) replication is substantially impaired. Previously, we have shown that the nucleoprotein of FluB (BNP) can inhibit FluA polymerase machinery, retarding the growth of FluA. However, the molecular mechanism underlying this inhibitory action awaited further investigation. Here, we provide evidence that BNP hinders the proper formation of FluA polymerase complex by competitively binding to the nucleoprotein of FluA. To exert this inhibitory effect, BNP must be localized in the nucleus. The interaction does not require the presence of the viral RNA but needs an intact BNP RNA-binding motif. The results highlight the novel role of BNP as an anti-influenza A viral agent and provide insights into the mechanism of intertypic interference.